HOME >> BIOLOGY >> NEWS
Growth disorder gene plays a big role in normal size variation

The presence of a small number of discrete forms - as you find in a classic Mendelian trait like eye color - suggests that the phenotype is controlled by a very small number of genes. In contrast, a complex trait such as body size is influenced by multiple genes as well as environmental factors, giving rise to a continuous spectrum of phenotypes. This causal complexity makes discovery of the genetic determinants of the trait - so-called quantitative trait loci (QTLs) - very difficult. In the open-access journal PLoS Biology, Fiona Oliver, Julian Christians, and colleagues extend their work on a single QTL with a large effect on body size variation in mice, and show that the responsible gene is one already linked to a Mendelian growth disorder in humans.

In this study, the authors further refined the map of a QTL on the X chromosome associated with a 20% difference in growth rate of mice, and found it contains only four genes: glypican-3 and glypican-4 (Gpc3 and Gpc4), and two other genes of unknown function. The glypicans are membrane-bound growth regulators; loss of function of Gpc3 in humans causes a rare syndrome of overgrowth, skeletal and other abnormalities, and neonatal death. In Gpc3, but not the others, size correlated with a significant difference in gene expression: larger mice had low levels of the messenger RNA, and smaller mice had high levels - the same pattern seen in the human loss-of-function disorder. The authors identified several non-coding polymorphisms in Gpc3 that differed between the two forms, although it remains to be seen whether the differential effect on growth is due to these or other DNA differences nearby.

The results from this study point out an important feature of inheritance, namely, that a gene implicated in a Mendelian trait can also contribute to quantitative variation. While catastrophic expression failure, such as a loss of function, can cause disease, smaller changes in expression of the same
'"/>

Contact: Paul Ocampo
pocampo@plos.org
415-624-1224
Public Library of Science
4-Apr-2005


Page: 1 2

Related biology news :

1. Growth factors and environment combine to increase brain maturation
2. Growth factor signals influence balance between normal growth and cancerous growth
3. Growth factor triggers growth of new blood vessels in the heart
4. Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons
5. Growth hormone is made in the brain, report scientists
6. Growth hormone, obesity can trigger sleep apnea in some kids
7. Growth in biomass could put US on road to energy independence
8. Growth factor in baby formula could reduce NEC, most devastating GI disease in preemies
9. Growth in the sea comes down to a struggle for iron
10. Growth of common skin cancer blocked in gene-switch mice
11. Growth factors confer immortality to sperm-generating stem cells

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Growth disorder gene plays big role normal size variation

(Date:6/23/2015)... GARDENS, Fla. , June 23, 2015 ... identity management and authentication solutions, today announced enhanced ... strong, multi-factor authentication solution.  The enhancements build ... use of the DigitalPersona Altus platform and ... reader compatibility. In today,s environment ...
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 /PRNewswire/ ...   Produktlinie mit DNA-Tests verbessert den Analyseprozess und senkt ... ; Frankfurt Prime Standard: QIA) hat heute in den ... Investigator ® für die ... neuen Kits zur Erstellung genetischer Fingerabdrücke bieten eine integrierte ...
(Date:6/17/2015)... BEACH GARDENS, Fla. , June 17, 2015 ... management solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... fast casual sandwich chain, to increase security, improve ... Crossmatch fingerprint readers enable instant, non-repudiable identity confirmation ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
(Date:7/2/2015)... ... July 02, 2015 , ... ... of surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, ... largest provider of surgical instruments to the Spine Industry. The acquisition of Turner ...
(Date:7/1/2015)... BURLINGTON, Mass. , July 1, 2015 /PRNewswire/ ... three most frequently cited advantages of Otezla are ... favorable safety profile, as reported by surveyed rheumatologists. ... and launched for the treatment of active psoriatic ... . The current standard of care includes conventional ...
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business ... to lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s ... cash prizes of US$15,000 and a period of expert mentorship from a senior industry ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: